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Abstract: In the endeavor to obtain new antitrypanosomal agents, particularly sesquiterpene lactones,
from Kenyan plants of the family Asteraceae, Vernonia cinerascens Sch. Bip. was investigated.
Bioactivity-guided fractionation and isolation in conjunction with LC/MS-based dereplication has led
to the identification of vernodalol (1) and isolation of vernodalin (2), 11β,13-dihydrovernodalin (3),
11β,13-dihydrovernolide (4), vernolide (5), 11β,13-dihydrohydroxyvernolide (6), hydroxyvernolide (7),
and a new germacrolide type sesquiterpene lactone vernocinerascolide (8) from the dichloromethane
extract of V. cinerascens leaves. Compounds 3–8 were characterized by extensive analysis of their
1D and 2D NMR spectroscopic and HR/MS spectrometric data. All the compounds were evaluated
for their in vitro biological activity against bloodstream forms of Trypanosoma brucei rhodesiense
and for cytotoxicity against the mammalian cell line L6. Vernodalin (2) was the most active
compound with an IC50 value of 0.16 µM and a selectivity index of 35. Its closely related congener
11β,13-dihydrovernodalin (3) registered an IC50 value of 1.1 µM and a selectivity index of 4.2.
Keywords: Asteraceae; sesquiterpene lactones; Vernonia cinerascens; Trypanosoma brucei rhodesiense;
antitrypanosomal activity
1. Introduction
Human African trypanosomiasis (HAT or sleeping sickness), Chagas disease, and leishmaniases
are some of the most neglected diseases among the eighteen neglected tropical diseases according
to WHO [1,2]. The mentioned diseases are caused by protozoan parasites of the trypanosomatid
family, order kinetoplastida, namely Trypanosoma brucei subsp., Trypanosoma cruzi, and Leishamania spp,
respectively, which are transmitted by insect vectors [3–6]. Millions of people are affected so these
diseases are a big public health concern, and more since the affected populations form a non-lucrative
sector for drug development [5–8]. Moreover, the available drugs for the treatment of these infections,
which were developed more than 50 years ago, are highly toxic, have a poor efficacy, and exhibit
increasing drug resistance [4,5]. Therefore, new drugs are required; in particular, those that are
appropriate for resource-limited rural health systems. Natural products have, in many instances,
shown high activity against the mentioned parasites [9,10].
Plants of the family Asteraceae are a rich source of sesquiterpene lactones (STLs) [11–17], which
have been reported to have a wide range of biological activity such as anti-inflammatory, cytotoxic,
antiplasmodial, and antitrypanosomal, among others [18–23]. Previous work in our group has shown
that STLs are good antiprotozoal agents, particularly against T. brucei rhodesiense, the causative agent
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of the East African form of HAT, and therefore, could be of interest for drug discovery [17,24–26].
Very recently, we reported on antitrypanosomal STLs from Vernonia lasiopus with vernolepin as the
most active compound from this plant [15]. In continuation of the study on STLs from this interesting
plant genus with potential antitrypanosomal activity, we have now investigated Vernonia cinerascens
Sch. Bip. (Asteraceae, subfamily Cichorioideae, tribe Vernonieae), which is an erect, highly branched
annual herb that is 0.3–2 m tall [27,28]. It is native to Africa (Sudan, Ethiopia, Uganda, Kenya,
Tanzania, Angola, Zimbabwe, Botswana, Namibia, South Africa) and Tropical Asia (India) [27]. It is
used ethnomedicinally to treat urinary tract infections, male sterility, internal ulcers, constipation,
navel aches, and gastritis [29,30]. Hirsutinolide type STLs have previously been reported from
this plant [30,31], in addition to vanillic acid, isoferulic acid, caffeic acid, methyl gallate, uridine,
3′-methylquercetin, and quercetin [32]. We report herein on the antitrypanosomal activity of the
dichloromethane leaf extract of this plant and its isolated constituents.
2. Results and Discussion
The dichloromethane (CH2Cl2) extract obtained from leaves of V. cinerascens was tested for in vitro
antiprotozoal activity against Trypanosoma brucei rhodesiense (Tbr) (STIB 900 strain) trypomastigotes,
T. cruzi (Tcr) (Tulahuen C4 strain) amastigotes, Leishmania donovani (Ldon) (MHOM-ET-67/L82 strain)
axenic amastigotes, and Plasmodium falciparum (Pf ) (NF54 strain) intra-erythrocytic forms. It was also
evaluated for in vitro cytotoxicity against mammalian cells, specifically the rat-skeletal myoblast cell
line L6. The extract was highly potent against Tbr with an IC50 value of 0.24 µg/mL and moderately
active against Ldon as well as Pf with IC50 values of 4.0 and 5.0 µg/mL, respectively. The extract
exhibited low activity against Tcr with an IC50 value of 16.4 µg/mL, but was moderately cytotoxic with
an IC50 value of 6.1 µg/mL against the L6 cell line. Therefore, the CH2Cl2 extract was fractionated by
silica gel column chromatography and representative fractions were subjected to bioactivity testing
against Tbr (STIB 900 strain) trypomastigotes. Fractions F5, F6, F8, and F9 showed IC50 values of 3.4,
1.4, 0.17, and 2.1 µg/mL, respectively.
The most active Fraction, F8, was analyzed by UHPLC/+ESIQTOFMS/MS and vernodalol (1),
vernodalin (2), and 11β,13-dihydrovernodalin (3) were dereplicated (see Figure S1). These compounds
had been isolated from V. lasiopus in our previous study and shown to have in vitro antiTbr activity with
IC50 values of 0.26 µM and 0.07 µg/mL for compound 1 and a mixture of compounds 2 and 3 (in the
ratio of 2:1), respectively, which could not be further separated due to the low amount obtained [17].
In the present study, vernodalin (2) and 11β,13-dihydrovernodalin (3) could be isolated in an attempt to
determine their individual bioactivity. Through preparative purification of F6 and F9, compounds 4–8
were obtained. The structures of all isolated compounds were unambiguously confirmed
from their NMR spectroscopic data and HR/MS data (obtained by UHPLC/+ESIQTOFMS/MS
analysis). Except for the new compound 8, vernolide (4) [33], 11β,13-dihydrovernolide (5) [31,33],
hydroxyvernolide (6) [31], and 11β,13-dihydrohydroxyvernolide (7) [31] were identified, and all
analytical data obtained were in full agreement with those reported in literature.
Vernocinerascolide (8) was obtained as a colorless amorphous solid and determined to have the
molecular formula C19H22O8 by (+)-ESIQTOFMS/MS and was readily identified as a derivative of
the germacrolide hydroxyvernolide 6 [28]. The 1H and 13C NMR spectra of 8 were very similar to
those of 6. However, in 8, there was a carbonyl group (δC 195.9/δH 9.52) characteristic of a formyl
functional group. The C-15 (δC 195.5) formyl group was assigned based on its HMBC correlations
with H-3 and H-5 (Table 1). Moreover, HMBC correlations of H-15 (δH 9.52) with C-3 and C-4 were
observed. Additionally, in 8, there was an oxymethylene (δC 66.3/δH 4.07; 3.81) which replaced the
doubly oxygenated C-14 methine in 6. This indicated that the C-14-O bond on the C-14-O-C-15 bridge
was cleaved in 8. The β orientations of C-14, H-6, and H-8 were supported by NOESY correlations
among H-14, H-6, and H-8. Similarly, the NOESY correlation between H-1 and H-7 affirmed the α
orientation of H-1 and H-7. Thus, compound 8 was unambiguously assigned the depicted structure
(Figure 1). We propose the generic name vernocinerascolide for this new germacrolide.
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Table 1. NMR spectroscopic data of compound 8 (150 and 600 MHz, CDCl3).
Position δC δH (multi., J in Hz) HMBC
1 64.5, CH 2.75, dd (9.8, 4.9) 2, 3, 10
2 28.4, CH2
α 2.24, ddt [tt] (13.9, 4.8)
3, 10
β 1.58, m
3 23.37, CH2 2.51, td (13.5, 4.8) 1, 2, 4, 5, 15
4 144.9, C
5 149.3, CH 6.35, dd (10.6, 1.0) 3, 4, 7, 15
6 76.8, CH 6.10, dd (10.6, 1.5) 4, 7, 8, 11, 12
7 52.7, CH 3.01, ddd [dq] (9.9, 1.7) 5, 8, 9, 11, 12, 13
8 72.3, CH 5.58, ddd (11.5, 9.9, 3.4) 1′
9 47.2, CH2
β 2.83, m
1, 7, 8, 10, 14
α 1.43, ddd (13.2, 11.5, 1.4)
10 60.0, C
11 135.8, C
12 171.2, C
13 131.4, CH2
a 6.43, d (1.7)
7, 8, 11, 12b 5.78, d (1.6)
14 66.3, CH2
4.07, dd (11.0, 0.8)
1, 9, 103.81, dd (11.0, 1.4)
15 195.9, CH 9.52, d (1.0) 3, 4
1′ 167.4, C
2′ 141.8, C
3′ 128.9, CH2
a 6.21, dt [q] (0.9)
1′, 2′, 4′b 5.89, dt [q] (1.3)
4′ 64.9, CH2 4.29, dd [t] (1.1) 1′, 2′, 3′
All isolated STLs were tested in vitro for activity against Tbr. Vernodalin (2) was the most active
with an IC50 value of 0.16 µM and a selectivity index (SI) of 35. The 11β,13-dihydro derivative
of vernodalin, 3, had a reduced inhibition activity with an IC50 value of 1.1 µM. The reduction in
activity can be attributed to the loss of one of the Michael acceptor systems upon hydrogenation of
the C-11-C-13 exomethylene group. The Michael acceptors, α,β-unsaturated carbonyl groups, have
been shown to alkylate biological macromolecules, thus inhibiting their normal functions [20,24,25].
These groups are generally held responsible for the high and wide range of biological activities of
most STLs and it has been shown for other examples that the presence of more than one such system
in the structure can dramatically enhance the activity [20,24,25]. The contribution of these groups to
the biological activity of STLs is further corroborated by a comparison of the potency of vernolide (5)
and 11β,13-dihydrovernolide (4), which had IC50 values of 0.50 and 17 µM, respectively. Similarly,
hydroxyvernolide (7) and its congener 11β,13-dihydrohydroxyvernolide (6) registered IC50 values of
5.0 and 15 µM, respectively. The new germacrolide vernocinerascolide (8) had a moderate IC50 value
of 4.8 µM and an SI of 27 (Table 2).
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Figure 1. Sesquiterpene lactones isolated from V. cinerascens.
Table 2. In vitro antitrypanosomal and cytotoxic activity IC50 values of the isolated compounds 2–8 a.
Compound Tbr (µM) Cytotoxicity (µM) SI
2 0.16 ± 0.04 5.6 ± 0.0 35
3 1.1 ± 0.3 4.7 ± 0.4 4.2
4 17 ± 0 13 ± 2 0.8
5 0.50 ± 0.01 6.9 ± 0.0 13
6 15 ± 0 49 ± 1 3.2
7 5.0 ± 0.0 22 ± 1 4.3
8 4.8 ± 1.1 128 ± 1 27
PC b 0.003 ± 0.001 0.007 ± 0.001
a Data are means of two independent determinations ± absolute deviation; for activity of compound 1, see [15].
b PC—Positive control: melarsoprol (Tbr), and podophyllotoxin (cytotox. L6).
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3. Materials and Methods
3.1. General Experimental Procedures
Optical rotation was measured on a JASCO P-2000 polarimeter (Groß-Umstadt, Germany). NMR
spectra were recorded on a 600 MHz Agilent DD2 NMR spectrometer (Agilent Technologies, Santa
Clara, CA, USA) at 298 K in CDCl3. The solvent signals (1H: 7.260 ppm and 13C: 77.000 ppm)
were used to reference the spectra. MestReNOVA v. 11 (Mestrelab Research, Chemistry Software
Solutions, Santiago de Compostela, Spain) software was used to process and evaluate the spectra.
HRESIMS spectra were obtained on a UHPLC/+ESIQTOFMS/MS instrument with a Bruker Daltonics
micrOTOF-QII quadrupole/time-of-flight mass spectrometer (Bruker Daltonics, Bremen, Germany)
with an Apollo electrospray ion source operated in positive ionization mode. A comprehensive
description of the UHPLC/+ESIQTOFMS/MS instrument settings and elution systems has been given
elsewhere [17]. TLC was performed on precoated silica gel plates 60 F254 (Merck Chemicals GmbH,
Darmstadt, Germany) with solvent systems consisting of hexane and ethyl acetate as the mobile phase.
The plates were visualized under UV light at 254/360 nm and then sprayed with anisaldehyde/sulfuric
acid reagent and heated on a hot plate. Column chromatography was performed on silica gel 60,
0.063–0.2 mm (Macherey-Nagel, Düren, Germany). Preparative HPLC isolations were carried out
on a JASCO (Groß-Umstadt, Germany) preparative HPLC system (pump: PU-2087 plus; diode array
detector MD 2018 plus; column thermostat CO 2060 plus; autosampler AS 2055 plus; LC Net II ADC
Chromatography Data Solutions; sample injection loop: 2000 µL) on a preparative reversed-phase
column Reprosil 100 C18 (5 µm, 250 mm × 20 mm, Macherey-Nagel, Düren, Germany) with binary
gradients of the mobile phase consisting of water and MeOH.
3.2. Plant Material
The plant material of V. cinerascens was collected and identified in April 2016 in Narok (1.0768◦
S, 35.9533◦ E), Kenya, by S.T. Kariuki, a taxonomist at the Biological Sciences Department, Egerton
University, Kenya. A voucher specimen has been deposited at the Institute of Pharmaceutical Biology
and Phytochemistry, University of Muenster, Germany (voucher number Kimani, 04). The sample was
dried in the shade at ambient temperature to constant weight and then ground.
3.3. Extraction and Isolation
The powdered plant material (600 g) was exhaustively extracted with CH2Cl2 (4.5 L) in a soxhlet
apparatus and evaporated under vacuum, yielding 20.34 g of crude extract. The extract was tested for
in vitro activity against Tbr, Tcr, Ldon, and Pf. The extract was chromatographed on a silica gel column
(800 g) and eluted with hexane (2 L) to afford hexane fraction. The column was further eluted with
hexane-EtOAc (3:2, 1:1, 3:7, 1:2, 0:10, v/v) to yield nine fractions (F1–F9). The fractions were analyzed
by UHPLC/+ESIQTOFMS/MS and representative fractions subjected to bioactivity testing. Fraction
F6 (86.3 mg) was separated by preparative HPLC with an optimized mobile phase composed of water
(A) and methanol (B) using the following binary gradient conditions: 50% of B (0–5 min), 50–55% of B
(5–10 min), 55–60% of B (10–15 min), 60–70% of B (15–20 min), 70–80% of B (20–25 min), 80–100% of B
(25–30 min) which was held for 5 min, 100–50% of B (45–40 min) which was held for a further 4 min,
and a flow rate of 9 mL/min was maintained. This yielded compounds 4 (3.7 mg; tR: 23.83–24.90 min)
and 5 (6.4 mg; tR: 25.23–25.8 min). Upon analysis of fraction F8 by UHPLC/+ESIQTOFMS/MS,
compounds 1–3 were dereplicated. In order to isolate compounds 2 and 3, this fraction (99.2 mg) was
separated using silica gel 60 column chromatography with hexane-EtOAc (3:7, v/v) as the mobile
phase to yield two subfractions F81–F82. Subfraction F82 (33.1 mg) was then separated by preparative
HPLC using an optimized binary gradient mobile phase composed of water (A) and methanol (B) as
follows: 40% of B (0–10 min), 40–45% of B (10–15 min), 45–50% of B (15–20 min) which was held for
a further 5 min, 50–100% of B (25–30 min) which was held for 5 min, and 100–40% of B (45–40 min)
which was held for 4 min. The flow rate was maintained at 10 mL/min. This yielded compounds 2
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(4.2 mg; tR: 23.35–24.00 min) and 3 (3.7 mg; tR: 25.00–26.30 min). Similarly, the separation of fraction F9
(22 mg) by preparative HPLC, using an optimized binary gradient mobile phase composed of water
(A) and methanol (B), occurred as follows: 40% of B (0–10 min), 40–45% of B (10–15 min), 45–50% of B
(15–20 min) which was held for a further 5 min, 50–100% of B (25–30 min) which was held for 5 min,
and 100–40% of B (45–40 min) which was held for 4 min at a flow rate of 10 mL/min, gave compounds 6
(3.7 mg; tR: 14.03–15.10 min), 7 (3.5 mg; tR: 11.57–12.93 min), and 8 (2.8 mg; tR: 9.13–9.84 min).
3.4. Analytical Data
Vernocinerascolide 8: Colorless armophous solid; [α]18D +28 (c 0.1, MeOH);
1H and 13C NMR
(CDCl3), see Table 1; (+)HRESIMS m/z 379.3822 [M + H]+ (calcd for C19H23O8, 379.1393); 396.4218
[M + NH4]+ (calcd for C19H26NO8, 396.1658); 401.3785 [M + Na]+ (calcd for C19H22O8Na, 401.1212);
UHPLC/+ESIQTOFMS tR: 5.33 min.
3.5. In Vitro Bioassays
In vitro bioactivity tests were performed as previously described [24] against Tbr (bloodstream
trypomastigotes, STIB 900 strain), Tcr (amastigotes, Tulahuen C4 strain), Ldon (axenic amastigotes,
MHOM-ET-67/L82 strain), and Pf (intraerythrocytic forms, NF54 strain), and the cytotoxicity test was
conducted against mammalian cells (L6 cell line from rat-skeletal myoblasts) at the Swiss Tropical and
Public Health Institute (Swiss TPH, Basel, Switzerland).
4. Conclusions
In summary, the search for novel antiprotozoal agents from V. cinerascens is described in this work.
The elemanolide type STLs vernodalol (1), vernodalin (2), and 11β,13-dihydrovernodalin (3) were
dereplicated from the dichloromethane extract of V. cinerascens leaves. Moreover, isolation and the
structure identification of a new germacrolide type STL vernocinerascolide (8), together with four
known compounds (4–7) of a similar type, are described. These compounds were obtained from the
leaves of V. cinerascens for the first time. In addition, compounds 2–8 displayed strong or moderate
antitrypanosomal activity against Tbr blood stream forms and compound 2 was the most active with
an IC50 value of 0.16 µM and an SI value of 35.2. Due to this considerably high activity, this compound
warrants further investigations such as in vivo and mechanism of action studies.
Supplementary Materials: The UHPLC/+ESIQTOFMS/MS chromatograms and spectra of compounds 1–3 and
8, and 1D and 2D NMR spectra of compound 8 as supplementary Figures S1–S8 available online.
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